Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

11.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.9K
Kendall's Tau Test01:16

Kendall's Tau Test

1.2K
Kendall's tau test, also known as the Kendall rank coefficient test, is a nonparametric method for assessing association between two variables. This test is particularly useful for identifying significant correlations when the distributions of the sample and population are unknown. Developed in 1938 by the British statistician Sir Maurice George Kendall, the tau coefficient (denoted as τ) serves as a rank correlation coefficient, with values ranging from -1 to +1.
A τ value of +1 indicates...
1.2K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

368
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
368
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.3K
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

231
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
231
Sustainable Development01:43

Sustainable Development

15.2K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic nanoliposome vaccine targeting multiple Aβ and tau epitopes reduces AD-like brain pathologies and rescues cognitive deficits in 3xTg-AD mice.

Brain, behavior, & immunity - health·2026
Same author

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model.

Brain, behavior, and immunity·2024
Same author

Diabetic Ketoacidosis Induces Tau Hyperphosphorylation in Rat Brain.

Journal of Alzheimer's disease reports·2024
Same author

Two simple assays for assessing the seeding activity of proteopathic tau.

Frontiers in aging neuroscience·2023
Same author

Gut Microbiota and Immunotherapy for Alzheimer's Disease.

International journal of molecular sciences·2022
Same author

Tau antibody 77G7 targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation.

CNS neuroscience & therapeutics·2022
Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational Risk assessment.

Expert opinion on drug discovery·2026
Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026
Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026
Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026
Same journal

Epigenetic reactivation in Friedreich's ataxia from benzamides to gene‑targeted chimeras.

Expert opinion on drug discovery·2026
Same journal

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Expert opinion on drug discovery·2026
See all related articles

Related Experiment Video

Updated: Feb 13, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

19.8K

Recent developments with tau-based drug discovery.

Khalid Iqbal1, Fei Liu1, Cheng-Xin Gong1

  • 1a Department of Neurochemistry, Inge Grundke-Iqbal Research Floor , New York State Institute for Basic Research in Developmental Disabilities , Staten Island , NY , USA.

Expert Opinion on Drug Discovery
|March 2, 2018
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) lacks effective treatments. Targeting abnormal tau protein, a hallmark of AD and tauopathies, shows promise, with tau immunotherapy offering significant therapeutic potential for neurodegenerative diseases.

Keywords:
Alzheimer’s diseasehyperphosphorylation of taumicrotubule-associated protein tauneurogenesisneuronal connectivityneurotrophic supportsynaptic plasticitytauopathies

More Related Videos

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.0K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.3K

Related Experiment Videos

Last Updated: Feb 13, 2026

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
09:49

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

19.8K
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

9.0K
Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

1.3K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is a leading cause of dementia with no current preventative or inhibitory treatments.
  • Intraneuronal hyperphosphorylated tau protein is a key pathological hallmark of AD and tauopathies.

Purpose of the Study:

  • To review the nature and mechanisms of tau pathology.
  • To explore drug discovery options and recent developments in tau-based therapeutics for Alzheimer's disease.

Main Methods:

  • Literature review using PubMed.
  • Information gathering on tau-based AD clinical trials via clinicaltrials.gov and Google search.

Main Results:

  • Tau pathology is a central feature of Alzheimer's disease and related tauopathies.
  • Several drug discovery avenues and therapeutic strategies targeting tau are under investigation.

Conclusions:

  • Loss of neuronal connectivity is linked to tau hyperphosphorylation and represents a critical therapeutic target.
  • Restoring neuronal connectivity and reducing tau hyperphosphorylation are promising therapeutic strategies.
  • Tau immunotherapy demonstrates high potential for treating Alzheimer's disease and tauopathies.